Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
2.
Nitric Oxide ; 84: 30-37, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30630056

ABSTRACT

Primary S-nitrosothiols (RSNOs) have received significant attention for their ability to modulate NO signaling in many physiological and pathophysiological processes. Such actions and their potential pharmaceutical uses demand a better knowledge of their stability in aqueous solutions. Herein, we investigated the effects of concentration, temperature, pH, room light and metal ions on the long-term kinetic behavior of two representative primary RSNOs, S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylcysteine (SNAC). The thermal decomposition of GSNO and SNAC were shown to be affected by the auto-catalytic action of the thiyl radicals. At 25 °C in the dark and protected from the catalytic action of metal ions, GSNO and SNAC solutions 1 mM showed half-lives of 49 and 76 days, and apparent activation energies of 84 ±â€¯14 and 90 ±â€¯6 kJ mol-1, respectively. Both GSNO and SNAC exhibited increased stability in the pH range 5-7. At high pH the decomposition pathway of GSNO involves the formation of an intermediate (GS-NO22-), which decomposes generating GSH and nitrite. GSNO solutions displayed lower sensitivity to the catalytic action of metal ions than SNAC and the exposure to room light led to a 5-fold increase in the initial rates of decomposition of both RSNOs. In all comparisons, SNAC solutions showed higher stability than GSNO solutions. These findings provide strategic information about the stability of GSNO and SNAC and may open new perspectives for their use as experimental or therapeutic NO donors.


Subject(s)
Acetylcysteine/analogs & derivatives , S-Nitrosoglutathione/chemistry , Acetylcysteine/chemical synthesis , Acetylcysteine/chemistry , Hydrogen-Ion Concentration , Kinetics , Light , S-Nitrosoglutathione/chemical synthesis , Temperature
3.
Sci Rep ; 8(1): 2440, 2018 02 05.
Article in English | MEDLINE | ID: mdl-29402918

ABSTRACT

The synthesis of anisotropic metallic nanoparticles (NPs) has been a field of intense and challenging research in the past decade. In this communication, we report on the reproducible and highly controllable synthesis of monodisperse branched gold nanoparticles in a droplet-based microfluidics platform. The process has been automated by adapting two different bulk synthetic strategies to microdroplets, acting as microreactors, for NP synthesis: a surfactant-free synthesis and a surfactant-assisted synthesis. Microdroplets were generated in two different microfluidic devices designed to accommodate the requirements of both bulk syntheses. The epitaxial growth of AuNSTs inside the microdroplets allowed for a fine control of reagent mixing and local concentrations during particle formation. This is the first time branched gold NPs have been synthesised in a microfluidics platform. The monodispersity of the product was comparable to the synthesis in bulk, proving the potential of this technology for the continuous synthesis of high quality anisotropic NPs with improved reproducibility.

4.
J Pharm Sci ; 105(1): 359-61, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26852866

ABSTRACT

The primary S-nitrosothiol, S-nitroso-N-acetylcysteine (SNAC) is a nitric oxide donor with potential pharmaceutical applications for the oral treatment of hepatic steatosis and cirrhosis and for protection against gastric acid-peptic disorders. However, its low thermal stability precludes the preparation of stable dosage forms based on presynthesized SNAC. In this study, we describe an innovative strategy for the oral administration of SNAC based on its intratablet formation via the S-nitrosation reaction of its parent stable thiol, N-acetyl-L-cysteine by nitrous acid during the absorption of water by the tablet. The proposed strategy allows for the manufacturing of thermally stable oral dosage forms for the controlled release of SNAC in the enteric medium.


Subject(s)
Nitric Oxide Donors/administration & dosage , Nitric Oxide Donors/chemistry , Nitroso Compounds/chemistry , S-Nitrosothiols/administration & dosage , S-Nitrosothiols/chemistry , Acetylcysteine/chemistry , Acetylcysteine/pharmacology , Administration, Oral , Chemistry, Pharmaceutical , Delayed-Action Preparations , Nitrosation , Nitrous Acid/chemistry , Tablets/chemistry , Water/chemistry
5.
Anal Chem ; 88(6): 3115-20, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26892256

ABSTRACT

S-Nitrosothiols (RSNOs) are carriers of nitric oxide (NO) and have important biological activities. We propose here the use of gold nanoparticles (AuNPs) and NO-selective amperometric microsensor for the detection and quantification of S-nitrosoglutathione (GSNO) as a step toward the determination of plasma RSNOs. AuNPs were used to decompose RSNOs with the quantitative release of free NO which was selectively detected with a NO microsensor. The optimal [GSNO]/[AuNPs] ratio was determined, corresponding to an excess of AuNP surface relative to the molar GSNO amount. Moreover, the influence of free plasma thiols on this method was investigated and a protocol based on the blocking of free thiols with iodoacetic acid, forming the carboxymethyl derivative of the cysteine residues, is proposed.


Subject(s)
Electrochemical Techniques/methods , Gold/chemistry , Metal Nanoparticles , S-Nitrosoglutathione/analysis , S-Nitrosothiols/blood , Humans
7.
J Antimicrob Chemother ; 68(11): 2561-8, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23788476

ABSTRACT

OBJECTIVES: This study was designed to verify the cytotoxic activity of S-nitrosoglutathione (GSNO) against intracellular Leishmania amastigotes and to test its efficacy as a topical treatment of localized cutaneous leishmaniasis (LCL) in Leishmania major- or Leishmania braziliensis-infected mice. METHODS: Cytotoxic activity of GSNO was verified in L. major-infected THP-1 macrophages. S-nitrosated proteins were detected by immunofluorescence. Topical treatment was done by daily application of a solution of GSNO in PBS to the skin ulcer of Leishmania-infected mice. BALB/c and interferon-γ-knockout (IFN-γ-KO) C57BL/6 mice were infected with L. major and L. braziliensis, respectively. Ulcer size was measured weekly and the parasite loads were determined in the lesion and lymph nodes. Controls received PBS topically or amphotericin B (AMB) intravenously. RESULTS: The number of intracellular L. major amastigotes was markedly reduced in GSNO-treated cultures; in these, staining for S-nitrosated proteins was present in the cytoplasm and colocalized with intracellular amastigotes. Topical treatment with GSNO of L. major ulcers in BALB/c mice suppressed lesion growth, reduced the parasite load and induced healing comparable to the effect of intravenously administered AMB. Topical GSNO treatment was also efficient at suppressing lesion growth in IFN-γ-KO mice infected with L. braziliensis. CONCLUSIONS: GSNO is cytotoxic to intracellular L. major amastigotes in vitro and had a healing effect on LCL caused by L. major and L. braziliensis in mice. These positive results on the topical therapeutic effect of GSNO in mouse leishmaniasis infections provide the experimental basis for a possible future trial in the treatment of human LCL.


Subject(s)
Antiparasitic Agents/administration & dosage , Leishmania braziliensis/drug effects , Leishmania major/drug effects , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/parasitology , S-Nitrosoglutathione/administration & dosage , Administration, Topical , Animals , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Parasite Load , Skin/parasitology , Skin/pathology , Treatment Outcome , Ulcer/parasitology , Ulcer/pathology
8.
Colloids Surf B Biointerfaces ; 108: 178-84, 2013 Aug 01.
Article in English | MEDLINE | ID: mdl-23545088

ABSTRACT

Clinical complications of implantable polypropylene (PP) meshes used to repair urinary incontinence and vaginal prolapse may be associated with their low surface energy and consequent poor tissue integration. For improving tissue integration, we impregnated monofilament PP meshes with physically crosslinked poly(vinyl alcohol) (PVA), resulting in PVA deposits tightly attached inside the knot spaces of the PP knit. While preserving the mesh porosity, the PVA deposits acted as an array of hydrophilic regions leading to a great increase in the overall mesh wettability, reflected by a contact angle decrease from 111 to ca. 66°. The PVA deposits were also used as reservoirs for the local release of S-nitrosoglutathione (GSNO), a nitric oxide (NO) donor. Plain and impregnated PP meshes (1.0cm×1.0cm) were implanted in the subcutaneous tissue of 21 adult female Wistar rats. Histological analysis of the abdominal wall 21 days after the surgeries revealed lower edema and greater angiogenesis while a marked decrement of NOx concentration in the tissue surrounding the impregnated meshes was observed after 2 days. These results indicate that PVA and PVA/GSNO impregnation might be a new strategy for decreasing the frequency of mesh extrusion after PP mesh implants.


Subject(s)
Abdominal Wall/blood supply , Biocompatible Materials/chemistry , Nitric Oxide Donors/chemistry , Polypropylenes/chemistry , Polyvinyl Alcohol/chemistry , S-Nitrosoglutathione/chemistry , Abdominal Wall/surgery , Animals , Biocompatible Materials/pharmacology , Female , Microscopy, Electron, Scanning , Neovascularization, Physiologic , Nitric Oxide/metabolism , Polyvinyl Alcohol/pharmacokinetics , Rats , Rats, Wistar , S-Nitrosoglutathione/pharmacokinetics , Surgical Mesh , Wettability
9.
Clin Ophthalmol ; 6: 1907-14, 2012.
Article in English | MEDLINE | ID: mdl-23204833

ABSTRACT

BACKGROUND: The purpose of this study was to evaluate the antimicrobial activity of two nitric oxide donors, ie, S-nitrosoglutathione (GSNO) and S-nitroso-N-acetylcysteine (SNAC), against clinical isolates from patients with infectious keratitis. METHODS: Reference broth microdilution assays were performed to determine the minimum inhibitory and bactericidal concentrations for GSNO and SNAC against four American Type Culture Collection strains and 52 clinical isolates from patients with infectious keratitis as follows: 14 (26.9%) Pseudomonas species; 13 (25.0%) coagulase-negative Staphylococci; 10 (19.2%) Staphylococcus aureus; nine (17.3%) Serratia marcescens; and six (11.5%) Enterobacter aerogenes. Sterility control and bacterial growth control were also performed. RESULTS: SNAC showed lower minimum inhibitory and bactericidal concentrations than GSNO for all clinical isolates from patients with infectious keratitis. For Gram-positive bacteria, mean minimum inhibitory and bactericidal concentrations were 2.1 ± 1.3 and 8.6 ± 3.8 mM for SNAC and 4.6 ± 3.2 and 21.5 ± 12.5 mM for GSNO (P < 0.01). For Gram-negative bacteria, mean minimum inhibitory and bactericidal concentrations were 3.3 ± 1.4 and 6.1 ± 3.4 mM for SNAC and 12.4 ± 5.4 and 26.5 ± 10.1 mM for GSNO (P < 0.01). The minimum bactericidal to inhibitory concentration ratio was ≤8 in 100% of all isolates tested for SNAC and in 94.2% tested for GSNO. CONCLUSIONS: SNAC and GSNO had effective inhibitory and bactericidal effects against bacterial isolates from keratitis. SNAC showed greater antimicrobial activity than GSNO against all bacteria. Gram-positive bacteria were more susceptible to the inhibitory and bactericidal effects of the S-nitrosothiols.

10.
J Periodontol ; 83(4): 514-21, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21910597

ABSTRACT

BACKGROUND: S-nitrosoglutathione (GSNO) is a nitric oxide donor that may exert antioxidant, anti-inflammatory, and microbicidal actions and is thus a potential drug for the topical treatment of periodontitis. In this study, the effect of intragingival injections of GSNO-containing polyvinylpyrrolidone (PVP) formulations is evaluated in a rat model of periodontitis. METHODS: Periodontal disease was induced by placing a sterilized nylon (000) thread ligature around the cervix of the second left upper molar of the animals, which received intragingival injections of PVP; saline; or PVP/GSNO solutions which corresponded to GSNO doses of 25, 100, and 500 nmol; 1 hour before periodontitis induction, and thereafter, daily for 11 days. RESULTS: PVP/GSNO formulations at doses of 25 and/or 100, but not 500 nmol caused significant inhibition of alveolar bone loss, increase of bone alkaline phosphatase, decrease of myeloperoxidase activity, as well as significant reduction of inflammatory and oxidative stress markers when compared to saline and PVP groups. These effects were also associated with a decrease of matrix metalloproteinases 1 and 8, inducible nitric oxide synthase, and nuclear factor-κB immunostaining in the periodontium. CONCLUSION: Local intragingival injections of GSNO reduces inflammation and bone loss in experimental periodontal disease.


Subject(s)
Alveolar Bone Loss/prevention & control , Anti-Inflammatory Agents/therapeutic use , Nitric Oxide Donors/therapeutic use , Periodontitis/prevention & control , S-Nitrosoglutathione/therapeutic use , Alkaline Phosphatase/drug effects , Alveolar Bone Loss/enzymology , Alveolar Process/drug effects , Alveolar Process/enzymology , Animals , Anti-Inflammatory Agents/administration & dosage , Biomarkers/analysis , Bone Resorption/prevention & control , Disease Models, Animal , Gingiva , Injections , Interleukin-1beta/drug effects , Lipid Peroxidation/drug effects , Matrix Metalloproteinase Inhibitors , NF-kappa B/antagonists & inhibitors , Nitric Oxide Donors/administration & dosage , Nitric Oxide Synthase Type II/antagonists & inhibitors , Oxidative Stress/drug effects , Peroxidase/antagonists & inhibitors , Pharmaceutic Aids , Povidone , Rats , Rats, Wistar , S-Nitrosoglutathione/administration & dosage , Sodium Chloride , Tumor Necrosis Factor-alpha/drug effects
11.
J Biomed Mater Res B Appl Biomater ; 93(2): 416-24, 2010 May.
Article in English | MEDLINE | ID: mdl-20101734

ABSTRACT

Poly(vinyl alcohol) (PVA) is a biocompatible polymer already used in several pharmaceutical products. The purpose of this work was to investigate the influence of freezing-thawing cycles (F/T) on the in vitro diffusion and skin vasodilator properties of S-nitrosoglutathione (GSNO)-releasing PVA films. Films subjected to 1-, 3-, and 5-F/T showed an increase in crystallinity, which is associated with an increase in the radius of gyration of macropores from 155 to 180 nm. Diffusion coefficients (D) of GSNO decreased from 5.7 x 10(-7) to 2.0 x 10(-7) cm(2) s(-1) in 1 and 3 F/T films, respectively, and were inversely correlated with the increase in crystallinity, whereas 5-F/T films showed an anomalous increase in D (5.0 x 10(-7) cm(2) s(-1)). Topical release of GSNO from PVA films on the skin of healthy volunteers led to local vasodilation measured by laser Doppler flowmetry. A higher increase in local blood flow was observed for 5-F/T films reaching maximum tissue perfusion at 45 min with return toward basal level after 45 min, whereas 1-F/T films led to a lower increase in blood flow up to 98 min. These results show that F/T treatment can be used to modulate the diffusion properties and the topical vasodilator profile of GSNO-containing PVA films, what might allow the use of these materials as dermal wound dressings or for promoting local vasodilation in ischemic tissues.


Subject(s)
Biocompatible Materials , Drug Delivery Systems , Membranes, Artificial , Polyvinyl Alcohol , S-Nitrosoglutathione/pharmacokinetics , Vasodilator Agents/pharmacokinetics , Administration, Topical , Adult , Blood Flow Velocity/drug effects , Female , Humans , Ischemia/drug therapy , Male , Porosity , S-Nitrosoglutathione/administration & dosage , Skin/blood supply , Vasodilation/drug effects , Vasodilator Agents/administration & dosage
13.
Eur J Obstet Gynecol Reprod Biol ; 148(1): 35-9, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19900744

ABSTRACT

OBJECTIVE: In gastroschisis there is herniation of the fetal bowel into the amniotic cavity that results in severe intestinal dysfunction. In order to reduce bowel exposure to amniotic fluid we used a hydrogel of N-isopropylacrylamide copolymerized with acrylic acid (P(NIPAAm-co-AAc)) to coat the herniated bowel through the use of a fibrin adhesive (Beriplast). STUDY DESIGN: Gastroschisis was created in fetuses of 31 pregnant Sprague-Dawley rats by evisceration of the bowel through a right paramedian incision in the abdominal wall on day 18.5 of pregnancy. The fetuses were separated in four groups of 12 fetuses: control (C), gastroschisis (G), gastroschisis+fibrin adhesive (GA) and gastroschisis+fibrin adhesive+dry hydrogel (GAH). Animals were harvested at day 21.5 of pregnancy and the hydrogel was removed. Fetuses and bowels were weighed and morphometric analysis was performed. Isoelectric focusing of the amniotic fluid determined its electrical charge. We evaluated the hydrogel swelling ratio (Q) in the amniotic fluid. Histological analysis and scanning electronic microscopy (SEM) of the bowel and hydrogel were performed. Our primary outcome was bowel intactness after hydrogel removal and our secondary outcome was the effectiveness of the hydrogel in protecting the bowel against amniotic fluid and its components. Differences among the groups were tested by the ANOVA and Tukey-Kramer post-test method and the statistical significance accepted was for p values <0.05. RESULTS: The mass of swollen hydrogel was 34 times the mass of dry hydrogel. Isoelectric focusing of the amniotic fluid showed that most of its proteins are negatively charged as the hydrogel. SEM showed that removal of the hydrogel did not damage bowel serosa. Bowel weight, diameter and wall thickness were similar between groups C and GAH but bowel diameter and wall thickness was significantly reduced in C and GAH compared to G and GA (p<0.001). CONCLUSION: The P(NIPAAm-co-AAc) hydrogel does not harm the bowel and provides a safe effective protection with reduction of bowel damage in gastroschisis.


Subject(s)
Acrylamides/therapeutic use , Gastroschisis/complications , Gastroschisis/drug therapy , Hydrogel, Polyethylene Glycol Dimethacrylate/therapeutic use , Inflammation/prevention & control , Polymers/therapeutic use , Amniotic Fluid/chemistry , Animals , Female , Fibrin Tissue Adhesive/therapeutic use , Intestines/abnormalities , Isoelectric Focusing , Microscopy, Electron, Scanning , Models, Animal , Pregnancy , Rats , Rats, Sprague-Dawley
14.
J Hepatol ; 45(5): 725-33, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16935387

ABSTRACT

BACKGROUND/AIMS: To understand the molecular mechanisms underlying non-alcoholic steatohepatitis (NASH) prevention by S-nitroso-N-acetylcysteine (SNAC), an NO donor that inhibits lipid peroxidation, we examined hepatic differentially expressed genes between ob/ob mice receiving or not SNAC treatment concomitantly with a methionine-choline deficient (MCD) diet. METHODS: Ob/ob mice were assigned to receive oral SNAC fed solution (MCD+SNAC group) or vehicle (MCD group) by gavage. After four weeks, histopathological analysis and microarray hybridizations were conducted in liver tissues from groups. GeneSifter system was used to identify differentially expressed genes and pathways according to Gene Ontology. RESULTS: NASH was absent in the MCD+SNAC group and no significant changes in food intake or body weight were observed in comparison to MCD group. After SNAC treatment, several genes belonging to oxidative phosphorylation, fatty acid biosynthesis, fatty acid metabolism and glutathione metabolism pathways were down-regulated in comparison to the MCD group. CONCLUSIONS: SNAC treatment promotes down regulation of several genes from fatty acid (FA) metabolism related pathways, possibly through abrogation of the cytotoxic effects of reactive oxygen species and lipid peroxides with consequent prevention of mitochondrial overload. Further studies are required to investigate the clinical implications of these findings, in attempt to develop novel therapeutic strategies for NAFLD treatment.


Subject(s)
Acetylcysteine/analogs & derivatives , Antioxidants/pharmacology , Fatty Liver/genetics , Fatty Liver/prevention & control , Lipid Peroxidation/drug effects , Acetylcysteine/pharmacology , Animals , Choline Deficiency/drug therapy , Down-Regulation , Fatty Acids/metabolism , Fatty Liver/metabolism , Gene Expression Profiling/methods , Male , Mice , Models, Animal , Oligonucleotide Array Sequence Analysis/methods , Reactive Oxygen Species , Up-Regulation
15.
Nitric Oxide ; 15(3): 209-16, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16527502

ABSTRACT

Nitric oxide (NO) is considered a key molecule in the defense against intracellular pathogens, particularly Leishmania. The expression of inducible nitric oxide synthase and consequent production of NO by infected macrophages has been shown to correlate with leishmaniasis resistance in the murine model as well as in human patients. Nitric oxide donors have been used successfully in the treatment of cutaneous leishmaniasis in humans, although their mechanisms of action are not fully understood. In the present work, the dose-dependent cytotoxic effects of the NO-donors S-nitroso-N-acetyl-l-cysteine (SNAC) and S-nitrosoglutathione (GSNO) against Leishmania were evaluated. GSNO inhibited the growth of Leishmania major and Leishmania amazonensis with in vitro 50% inhibitory concentrations (IC(50)) of 68.8+/-22.86 and 68.9+/-7.9 micromol L(-1), respectively. The IC(50) for SNAC against L. major and L. amazonensis were, respectively, 54.6+/-8.3 and 181.6+/-12.5 micromol L(-1). The leishmanicidal activity of GSNO, but not of SNAC, was reversed by ascorbic acid (AA) and dithiothreitol (DTT), suggesting that the mechanism of action of GSNO is related to the transnitrosation of parasite proteins. These results demonstrate that SNAC and GSNO have leishmanicidal activity, and are thus potential therapeutic agents against cutaneous leishmaniasis.


Subject(s)
Acetylcysteine/analogs & derivatives , Leishmania major/drug effects , Leishmaniasis, Cutaneous/drug therapy , Nitric Oxide Donors , S-Nitrosoglutathione , Acetylcysteine/pharmacology , Acetylcysteine/therapeutic use , Animals , Cell Survival/drug effects , Humans , Nitric Oxide/metabolism , Nitric Oxide Donors/pharmacology , Nitric Oxide Donors/therapeutic use , S-Nitrosoglutathione/pharmacology , S-Nitrosoglutathione/therapeutic use
16.
J Pharm Sci ; 94(5): 994-1003, 2005 May.
Article in English | MEDLINE | ID: mdl-15793801

ABSTRACT

Nitric oxide (NO) is responsible for biological actions in mammals, ranging from the control of arterial pressure to immunological responses. In this study, S-nitrosoglutathione (GSNO), a spontaneous NO donor, was incorporated in solid films of blended poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP) comprising a biomaterial with potential for the local delivery of NO. In dry conditions, the extinction of the absorption bands of GSNO was correlated with the increase of the absorption band of its dimmer, GS-SG, implying NO release through the homolytic cleavage of the S-N bond. Mass spectrometry was used to confirm and to monitor the release of free NO from solid PVA/PVP-GSNO films to the gas phase. Kinetic measurement based on the Griess reaction was used to show that solid PVA/PVP-GSNO films are also capable of releasing both NO and GSNO to aqueous solution trough diffusion. Storage experiments have shown that GSNO is highly stabilized in the dry PVA/PVP matrix. The results indicate that GSNO-containing PVA/PVP films may be used for delivering free NO and/or GSNO topically and controllably.


Subject(s)
Nitric Oxide Donors/administration & dosage , Nitric Oxide Donors/pharmacology , Pharmaceutic Aids/chemistry , Polyvinyl Alcohol/chemistry , Povidone/chemistry , S-Nitrosoglutathione/administration & dosage , S-Nitrosoglutathione/pharmacology , Administration, Topical , Diffusion , Kinetics , Mass Spectrometry , Oxidation-Reduction , Solutions , Solvents , Water
17.
Nitric Oxide ; 11(3): 263-72, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15566973

ABSTRACT

Incorporation of nitric oxide (NO) donors in non-toxic polymeric matrices can be a useful strategy for allowing topical NO delivery. We have incorporated the NO-donor S-nitrosoglutathione (GSNO) into a liquid poly(ethylene glycol) (PEG)/H2O matrix through the S-nitrosation of GSH by a NO/O2 gas mixture. Kinetic measurements of GSNO decomposition associated with NO release were performed at 25, 35, and 45 degrees C in the dark and under irradiation with UV/Vis light, lambda>480 nm and lambda=333 nm. NO release from the liquid matrix to the gas phase was confirmed by mass spectrometry. The PEG/H2O matrix stabilizes GSNO leading to expressive reductions in the initial rates of thermal and photochemical NO release, compared to aqueous GSNO solution. This matrix effect is assigned to diffusional constrains imposed on the escape of the NO and GS radicals formed in the solvent cage. This effect allows the storage of PEG-GSNO formulations for extended periods (more than 65 days at freezer) with negligible decomposition. PEG-GSNO formulation seems therefore to be applicable in topical NO delivery and GSNO displays potential as a percutaneous absorption enhancer. Moreover, the rate of NO release can be locally increased by irradiation with visible light.


Subject(s)
Drug Delivery Systems/methods , Nitric Oxide Donors/metabolism , Nitric Oxide/administration & dosage , Nitric Oxide/metabolism , Polyethylene Glycols/chemistry , S-Nitrosoglutathione/metabolism , Administration, Topical , Drug Delivery Systems/instrumentation , Kinetics , Nitric Oxide Donors/chemistry , Photochemistry , S-Nitrosoglutathione/chemistry , Solutions , Spectrum Analysis , Temperature
18.
Biomaterials ; 25(17): 3773-82, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15020153

ABSTRACT

The nitric oxide (NO) donor S-nitrosoglutathione (GSNO) was incorporated in solid polymeric films of poly(vinyl alcohol) (PVA), poly(vinyl pyrrolidone) (PVP) and blended PVA/PVP. These matrices were found to provide a great stabilization effect on the thermal decomposition of GSNO, leading to 8-16-fold reduction in the first-order rate constants of NO release, compared to aqueous GSNO solutions. PVA/PVP-GSNO released 90% of the NO supply, over a time period of 24h at 37 degrees C. Differential scanning calorimetry has confirmed the miscibility between the two polymeric components. Stress-strain analysis has shown an improvement of the mechanical property of PVA films in the PVA/PVP blend, which leads to an increase of 25% in the stress at break. Scanning electron microscopy has shown that the PVA/PVP-GSNO blend leads to a smooth coating of metallic surfaces. These properties, allied to the already known good biocompatibility of PVA and PVP, makes GSNO-containing PVA and PVA/PVP blend films good candidates for the local and controlled release of NO in target areas.


Subject(s)
Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Nitric Oxide/administration & dosage , Nitric Oxide/chemistry , Polyvinyl Alcohol/analogs & derivatives , Polyvinyl Alcohol/chemistry , Povidone/analogs & derivatives , Povidone/chemistry , Coated Materials, Biocompatible/chemistry , Diffusion , Drug Delivery Systems/methods , Elasticity , Kinetics , Materials Testing , Surface Properties , Temperature , Tensile Strength
19.
Nitric Oxide ; 7(1): 57-66, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12175821

ABSTRACT

S-Nitrosothiols (RSNOs) are potent vasodilators found naturally in vivo. A variety of synthetic RSNOs have been considered as potential nitric oxide (NO) donors for biomedical applications. We have characterized the hypotensive effect of the RSNO S-nitroso-N-acetylcysteine (SNAC) in normotensive and hypertensive conscious rats. SNAC reduced the medium arterial pressure in a dose-response manner in both normotensive and hypertensive animals. At the same doses (EC(50) of SNAC), SNAC showed a vasodilator effect in normotensive rats more potent and more prolonged than that of sodium nitroprusside (SNP). The hypotensive effect of SNAC was also more potent in methylene blue-treated rats, where the cGMP-dependent pathway had been blockaded. These data indicate that SNAC acts by both cGMP-dependent and cGMP-independent pathways. It was also shown that the thiol N-acetylcysteine (NAC) potentiates the action of SNP in hypertensive rats, pointing to the mediation of thiols in the vasodilator action of SNP in this condition. Such mediation may involve the formation of a more potent thiol complex with the nitroprusside anion or the transfer of NO to NAC, generating SNAC as a primary vasoactive species. The kinetic monitoring of the decomposition reactions of SNAC and SNP showed that both compounds are quite stable under the infusion conditions used. Therefore, their vasodilator action cannot be assigned to their breakdown with release of free NO in solution. As the two compounds are unlikely to cross the plasmalemma of smooth muscle cells, their actions are probably associated with the mediation of endogenous thiols in transnitrosation reactions.


Subject(s)
Acetylcysteine/analogs & derivatives , Acetylcysteine/pharmacology , Blood Pressure/drug effects , Hypertension/drug therapy , Acetylcysteine/administration & dosage , Animals , Cyclic GMP/metabolism , Dose-Response Relationship, Drug , Drug Stability , Drug Synergism , Drug Therapy, Combination , Male , Rats , Rats, Wistar , Sulfhydryl Compounds/metabolism , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...